Corticotropin (ACTH)-independent macronodular adrenal hyperplasia (AIMAH) is a heterogeneous condition in which cortisol secretion may be mediated by gastrointestinal peptide (GIP), vasopressin, catecholamines and other hormones. We studied the expression profile of AIMAH by genomic cDNA microarray analysis. Total RNA was extracted from eight tissues (three GIP-dependent) and compared to total RNA obtained from adrenal glands from 62 normal subjects. Genes had to be altered in 75% of the patients, and be up- or downregulated at a cutoff ratio of at least 2.0; 82 and 31 genes were found to be consistently up- and downregulated, respectively. Among the former were regulators of transcription, chromatin remodeling, and cell cycle and adhesion. Downregulated sequences included genes involved in immune responses and insulin signaling. Hierarchical clustering correlated with the two main AIMAH diagnostic groups: GIP-dependent and non-GIP-dependent. The genes encoding the 7B2 protein (SGNE1) and WNT1-inducible signaling pathway protein 2 (WISP2) were specifically overexpressed in the GIP-dependent AIMAH. For these, and six more genes, the data were validated by semiquantitative amplification in samples from a total of 32 patients (the original eight, six more cases of AIMAH, and 18 other adrenocortical hyperplasias and tumors) and the H295R adrenocortical cancer cell line. In conclusion, our data confirmed AIMAH's clinical heterogeneity by identifying molecularly distinct diagnostic subgroups. Several candidate genes that may be responsible for AIMAH formation and/or progression were also identified, suggesting pathways that affect the cell cycle, adhesion and transcription as possible mediators of adrenocortical hyperplasia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/sj.onc.1207277 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PDE11A is a phenotype modulator of Primary Bilateral Macronodular Adrenal Hyperplasia: results of a 334 patients' series.
J Clin Endocrinol Metab
January 2025
Institut Cochin, INSERM U1016, CNRS UMR8104, Paris Descartes University, Paris, France.
Purpose: Primary bilateral macronodular adrenal hyperplasia (PBMAH), the most common cause of Cushing's syndrome due to bilateral nodules, is a heterogeneous disease at the clinical, hormonal and morphological levels. ARMC5 inactivating pathogenic variants are causative of PBMAH and rare variants of PDE11A have been associated with PBMAH.
Methods: Leukocyte DNA of 354 PBMAH index cases was sequenced for ARMC5 and PDE11A genes by Next generation sequencing (NGS).
Case report: A 51-year-old diabetic patient with primary bilateral macronodular adrenal hyperplasia and primary hyperparathyroidism.
Front Endocrinol (Lausanne)
December 2024
Department of Endocrinology, Chengdu Second People's Hospital, Chengdu, China.
A 51-year-old female patient with diabetes mellitus and hypertension, exhibiting poor control of blood sugar and blood pressure, was unexpectedly found to have multiple large adrenal nodules, excessive cortisol secretion, and adrenocorticotropic hormone inhibition. Cortisol levels remained unresponsive to both low-dose and high-dose dexamethasone tests, leading to a diagnosis of primary bilateral macronodular adrenal hyperplasia. Concurrently, elevated blood calcium and parathyroid hormone levels, along with 99mTc-methoxyisobutyl isonitrile (99mTc-MIBI) imaging revealing increased 99mTc-MIBI uptake in the right inferior parathyroid gland, suggest the consideration of primary hyperparathyroidism.
View Article and Find Full Text PDFPrimary bilateral macronodular adrenal hyperplasia: A rare case report of Cushing syndrome and review of literature.
Medicine (Baltimore)
October 2024
Department of Endocrinology, Vali-Asr Hospital, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Article Synopsis
- Primary bilateral macronodular adrenal hyperplasia (PBMAH) is a rare condition that causes Cushing syndrome (CS) and can be challenging to diagnose, making up less than 2% of CS cases.
- The case involves a 52-year-old woman experiencing multiple symptoms including fever, fatigue, and bruising, leading to an eventual diagnosis of PBMAH after lab tests and an abdominal CT scan showed increased cortisol levels and adrenal masses.
- Although the patient underwent surgery to remove one adrenal gland and her symptoms improved, she continues to rely on glucocorticoid therapy a year later, highlighting the need for more research on effective treatment options for PBMAH.
The molecular genetics of adrenal cushing.
Hormones (Athens)
December 2024
Genomic and Signaling of Endocrine Tumors team, INSERM U1016, CNRS UMR8104, Cochin Institute, Paris Cité University, Paris, 75005, France.
Article Synopsis
- - Adrenal Cushing accounts for 20% of cases of hypercorticism, with unilateral cortisol-producing adenomas (benign tumors) being more common than malignant adrenocortical carcinoma (ACC) and bilateral adrenal diseases.
- - Key signaling pathways involved in these tumors include protein kinase A and Wnt/β-catenin, with genetic predispositions identified through research on familial cases and pangenomic sequencing.
- - ACC is often linked to TP53 mutations, particularly in children, and can be associated with various hereditary syndromes, while cortisol-producing adenomas show mutations primarily in PRKACA and CTNNB1.
Long-term outcome of unilateral adrenalectomy for primary bilateral macronodular adrenal hyperplasia.
Endocrine
October 2024
School of Medicine, Nankai University, Tianjin, China.
Article Synopsis
- The study investigates the long-term effectiveness of unilateral adrenalectomy (U-Adx) as a treatment for primary bilateral macronodular adrenal hyperplasia (PBMAH), a type of Cushing's syndrome, which traditionally required bilateral adrenalectomy but posed significant risks.
- Researchers evaluated 61 patients treated with U-Adx between 2004 and 2022, analyzing their postoperative biochemical outcomes and improving comorbidities such as hypertension and glucose metabolism.
- Results showed that about 50% of patients achieved initial remission within six months; however, a significant percentage experienced persistent hypercortisolism or recurrence at the last follow-up, highlighting the need for further understanding of prognostic predictors for
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!